THE IMPACT OF REGULATORY CHANGES IN PHARMACEUTICAL MARKET ACCESS AND PRICING: A COMPARATIVE ANALYSIS

Dissertation Submitted to

The IIHMR University, Jaipur

for the partial fulfilment for the award of the degree of

Master of Business Administration (MBA)

in

Pharmaceutical Management

By

Shubham Saini

Under the Supervision and Guidance of

Dr. Ashok Peepliwal

2024

Galcare

CERTIFICATE

OF RECOGNITION

This is to certify that

Mr. Shubham Saini

of 2022-2024 (batch) of IIHMR University has effectively learnt, performed and completed his Internship Thesis Project with Galcare Pharmaceutical Pvt Ltd from March 2024 to June 2024

We appreciate his active participation, conduct, mannerism and timely deliverables.

This certificate is being issued to meet the requirement of the University.

Irfan Ahmad
Senior Marketing Head

Date:- 01-07-2024

DECLARATION BY STUDENT

I hereby declare that this dissertation titled "**THE IMPACT OF REGULATORY CHANGES IN PHARMACEUTICAL MARKET ACCESS AND PRICING: A COMPARATIVE ANALYSIS**" is the bonafide record of my original research work. I declare that it has not been submitted to any other university or institution for the award of any degree or diploma. Information derived from the published or unpublished work of others has been duly acknowledged in the text.

Student Name: Shubham Saini

Date: 04/07/2024

(Signature) Shubha Saini

IIHMR UNIVERSITY

CERTIFICATE FROM FACULTY GUIDE AND SCHOOL DEAN

This is to certify that dissertation titled **THE IMPACT OF REGULATORY CHANGES IN PHARMACEUTICAL MARKET ACCESS AND PRICING: A COMPARATIVE ANALYSIS** is a record of the research work undertaken by **Shubham Saini** in partial fulfillment of the requirements for the award of the degree of MBA Pharmaceutical Management from the IIHMR University, Jaipur under my guidance and supervision and his/her approach to the research study has been sincere, scientific, and analytical.

Dr.Ashok Kumar Peepliwal
(Professor)
IIHMR University, Jaipur
Date:- 04/07/2024

Dr.Manthan D. Janodia
Dean SPM
IIHMR University, Jaipur
Date:- 04/07/2024

1, Prabhu Dayal Marg, Near Sanganer Airport, Jaipur- 302029, Rajasthan, India.
Ph.: 0141-3924700, 2791431- 32, E-mail: iihmr@iihmr.edu.in, Web.: www.iihmr.edu.in

Abstract

The pharmaceutical industry operates within a complex regulatory environment that has a significant impact on market access and pricing strategies. The study commences by analyzing the dynamic regulatory environment and emphasizing the historical context of pharmaceutical regulation and pricing control. This comparative analysis examines the influence of regulatory changes on the accessibility and pricing of pharmaceuticals in various locations, with a specific emphasis on the pricing strategies of pharmaceuticals in developing economies. The study examines the impact of Price regulation "Drug Price Control Order 2013" on the affordability and availability of drugs, as well as the connection between regulatory settings and pharmaceutical innovation. This study performs a comparative analysis to evaluate the impact of regulatory changes on the dynamics of the pharmaceutical market in various geographical regions in India. This study aims to identify shared patterns, inconsistencies, and strategic adjustments made by pharmaceutical companies by examining regulatory systems. The research objectives are successfully accomplished through the use of a comprehensive approach that integrated both quantitative and qualitative data sources. The influence of price regulation, specifically the "Drug Price regulation Order (DPCO) 2013", on the affordability and availability of medications between 2008 and 2018 was evaluated using descriptive statistics. The study analyzes the patterns in research, tactics for patent protection, and approaches to entering the market by pharmaceutical businesses in reaction to legislative reforms. This study also examines the impact of regulatory bodies in promoting a favorable atmosphere for pharmaceutical innovation while guaranteeing prompt availability of secure and efficient medications. The study's methodological approach combines rigorous statistical research with detailed qualitative observations, resulting in a comprehensive understanding of how regulatory settings influence the pharmaceutical industry's landscape. The present study employed secondary data gathering methods to ensure a thorough investigation of the influence of regulatory changes on the pharmaceutical business. "Regression models" were developed to examine the relationship between regulatory factors and markers of innovation. The findings highlight the nuanced effects of regulatory interventions on the availability, price, and progress of medications, providing useful insights into how different regulatory approaches impact market dynamics and the welfare of patients. This study emphasizes the importance of adaptable regulatory measures in ensuring a harmonious relationship between healthcare accessibility and the global pharmaceutical business.

Ultimately, this comparative research combines information from several regulatory contexts to offer insights into the intricate relationship between regulatory changes, pharmaceutical market entry, and pricing tactics. This highlights the significance of flexible regulatory frameworks that effectively balance incentives for innovation with the goals of affordability and patient availability. Future regulatory reforms must achieve a careful equilibrium between fostering pharmaceutical innovation and guaranteeing fair and affordable healthcare access on a global scale.

Keywords: Pharmaceutical industry, regulatory changes, market access, pricing strategies,

Table of Contents

Chapter-1

Introduction

1.1 Background

The pharmaceutical sector serves a crucial role in the healthcare system, as it is responsible for manufacturing and advertising medications, biological products, and medical equipment. These products are employed in the detection and treatment of ailments, and the industry also conducts research to create new products for the improvement of human welfare. The correlation between regulatory compliance and the concept of change control is indissoluble. Lack of adequate change control procedures poses a substantial danger of non-compliance within a pharmaceutical company's quality management system [1]. Given that the regulatory framework established for pharmaceuticals has been mostly applied to human biologic medications, researchers will now refer to them as "pharmaceuticals" and will expressly indicate any divergent treatment of biologics. The reason for strict control of pharmaceuticals is not due to inherent natural monopoly, as any market dominance held by specific items ultimately comes from patents given by the government. Regulation of market access, manufacture, and advertising is necessary because to the fact that the effectiveness and safety of products can have a significant impact on patient health, even if they may not be readily apparent [2].

The Regulatory Affairs department serves as the last authority for pharmaceutical papers within every pharmaceutical business, playing a crucial role in ensuring the compliance and market approval of medical products. The primary duty of every Regulatory Affairs department is to diligently adhere to the National Law in the target market. This involves acquiring and maintaining comprehensive knowledge of the procedures for product registration and other intricate details inside the legal framework, which are considered the regulators' domain of expertise. Regulatory Affairs serves as the custodian and central hub for documents that are prepared for submission by all departments within a pharmaceutical company [3].

Pharmaceutical markets are characterized by a lack of responsiveness to price changes, primarily because of widespread medical insurance coverage. Additionally, the patent system grants market strength to pharmaceutical companies by preventing the replication of novel

chemical compounds for a specific duration. This combination has prompted most countries to employ diverse methods to regulate the increase in medical expenses [4].

1.2 Regulatory Changes in Pharmaceutical

The regulatory framework in the Indian pharmaceutical business is of utmost importance due to the swift and continuous changes occurring at the international level, particularly in relation to "good manufacturing practices (GMP)", "good clinical practices (GCP)", and "good laboratory practices (GLP)". The Indian pharmaceutical industry is experiencing continuous growth and intensifying competition. As a result, regulatory bodies have been created to ensure the safety, efficacy and quality of pharmaceutical, as well as the accuracy and appropriateness of drug information available to the public [5].

The pharmaceutical products address the increasing challenge of a double disease burden in India. It examines the consequences of maintaining a public policy that aims to promote the growth of the domestic pharmaceutical industry in the "post-Trade Related Intellectual Property Rights" (TRIPS) Agreement era. An assessment is conducted to analyze the impact of policy design on two aspects: the sale of domestic firms to foreign buyers and the missed opportunities for product innovation in the pharmaceutical industry to improve healthcare in India and other developing nations [6].

The oversight of medical items has been progressively broadening since the early 20th century. Regulatory bodies are being developed in an escalating number of countries worldwide. Established entities are currently restructuring their processes and striving to achieve harmonization with organizations from other nations. The pharmaceutical, biotechnology, and medical devices sectors are subject to extensive regulations, making them some of the most tightly regulated industries globally. Regulatory affairs (RA) experts work in several sectors such as the pharmaceutical industry, government, academic research, and clinical facilities [7].

1.2.1 Principles of medicines regulatory functions

- The licensing process involves regulating the production, importation, exportation, distribution, promotion, and advertising of medicinal items.
- Conducting inspections and surveillance of makers, importers, wholesalers, and dispensers of medications.

- Ensuring the regulation and oversight of the quality of pharmaceutical products available in the market.
- Regulating the promotion and advertising of pharmaceuticals.
- Ensuring the safety of drugs that are being sold by collecting and analyzing reports of negative reactions.
- Offering autonomous knowledge regarding medications to experts and the general public [8].

1.3 Historical Evolution of Pharmaceutical Regulation

The pharmaceutical sector has consistently exhibited relatively low levels of concentration over its entire history, particularly in comparison to other industries that heavily invest in research and development and marketing [9]. In the past century, the pharmaceutical business has transformed from small-scale producers of patent medicines to large, research-oriented global corporations that exist today. Throughout its extensive history, the pharmaceutical industry has developed numerous new pharmaceuticals through a multitude of smaller, incremental innovations [10].

In accordance with the Drug Act of 1978, the Royal Drug Research Laboratory was designated as the national government organization responsible for ensuring the quality of medications. Subsequently, the Department of Drug Administration (DDA) was founded in 1979 under the Ministry of Forest and Soil Conservation, in compliance with the aforementioned Act. The primary goals of the "Drug Act" were to prevent the improper use or abuse of drugs and related pharmaceutical substances, as well as the dissemination of false or misleading information regarding their effectiveness and usage. Additionally, the act aimed to oversee and manage the production, marketing, distribution, import, export, storage, and utilization of drugs that are deemed unsafe, ineffective, or of substandard quality for public use [11].

1.4 Impact of Regulatory Changes on Drug Pricing

The rationale for implementing price regulation in the pharmaceutical market based on the lack of competition appears feeble when considering markets with medicines that have had their patents expire. Once the patent of a product expires, obstacles preventing entry into the market should vanish, as the formula for the active ingredient becomes publicly available, and other

companies should encounter little challenges in replicating the manufacturing method. The conventional justifications for price regulation, which were based on the ability of any firm to produce a generic version of a brand name product, have little support in economic theory. The disappearance of manufacturers' temporary market power and the probable reduction in the oligopolistic structure of several therapeutic submarkets are the reasons for this [12].

In 1993, reference pricing was introduced as a reimbursement system where patients receive a partial refund of the retail price when purchasing prescription drugs. Before “April 1, 2005” the reference price was determined by taking the lower value between the list price of a product’s own substitution group and the average price of the corresponding European market. Typically, when the costs of Danish items were lower than the average price in Europe, patients had little motivation to purchase the least expensive product. This is because the majority of the price difference between the cheapest product and the preferred alternative was covered by public health insurance. “On April 1, 2005” the reference prices were modified to become the lowest price among Danish items in the same substitution category. This modification was made in order to make patients more aware of price differences and to intensify competition [13].

In recent years, a number of nations, including Germany, Italy, and Australia, have attempted to decrease healthcare costs by implementing a system known as therapeutic reference pricing. This method involves determining drug reimbursement based on the concept of therapeutic equivalency. Reference pricing regulations categorize medications into several groups based on their active agents and/or indications; however the specific methods may differ. Drug reimbursement to the patient is determined by class, using a reference price that is established based on domestic pricing, typically giving more importance to lower costs [14].

1.4.1 “Pharmaceutical Pricing Policies” in developing countries

- **China**

In China, the Bureau of Pricing, which operates under the National Development and Reform Commission (NDRC), has historically been responsible for setting the prices of drugs and medical devices that are listed in the drug formulary. These prices are used for reimbursement purposes in publicly funded medical insurance programs, both at the national and provincial levels. The prices for each active ingredient and dosage form were calculated using the

manufacturers' declared costs, which were subsequently multiplied by markups to account for profits and the expenses related to research and development.

- **India**

Pharmaceutical pricing policies were officially implemented in India in 1963 through the "Drugs (Display of Prices) Order" of 1962 and the "Drugs Control of Prices Order" of 1963. These policies were established under the defence of India Rules, following the outbreak of war with China, and involved freezing drug prices. Upon the implementation of the "Drugs (costs Control) Order" of 1966, the government lacked the authority to lower pharmaceutical costs. However, government clearance was necessary for any price increases on specific drugs. The implementation of the "Drugs Prices Control Order of 1970" granted the government the authority to establish price limits for bulk drugs. This marked the first time that price limits were set for 18 specific bulk drugs, while the prices of the other bulk drugs were frozen and could not be increased without prior approval from the government.

- **Malaysia**

The Malaysian Ministry of Health, which is responsible for providing primary healthcare services in the public sector, controls the prices of medications in the public healthcare sector by enforcing the "Ministry of Health" medications "Formulary since 1983". This guarantees that the prices of medications in the public sector are lower in comparison to the commercial healthcare sector. The formulary consists of all pharmaceutical formulations that have been authorized by the "Drug List Review Panel" for government payment and accessibility in public healthcare facilities within the public healthcare sector [15].

1.4.2 Price regulation ("Drug Price Control Order 2013") on Drug Affordability and Availability

The World Health Assembly, in 2019, adopted a resolution endorsing the promotion of transparency about the pricing of pharmaceuticals. The resolution urged governments to thoroughly assess the impact of pricing rules on the affordability and availability of medical products. National governments utilize several policy measures to address market imperfections and oversee drug pricing and expenditures. The establishment of price regulation often leads to a decrease in pharmaceutical prices. Several nations employ a blend of policy instruments to attain

a balanced state between health policy and industrial policy goals. India has enforced price limitation since 1962, notably through the implementation of the “Drug Price Control Orders (DPCO)”. The most recent "Drug Price Control Order (DPCO)", 2013 was officially announced on 15 May 2013 to enforce the "National Pharmaceutical Pricing Policy (NPPP)", 2012. The primary goal of the NPPP was to provide an all-encompassing framework of standards and methods for determining the pricing of medications. The objective of this measure was to ensure that vital pharmaceuticals are accessible to the public at reasonable costs, while simultaneously cultivating an atmosphere that promotes innovation and competition to support the pharmaceutical sector [16].

In May 2013, the “Department of Pharmaceuticals (DOP)” in India implemented the “Drug Price Control Order (DPCO)” to regulate the prices of 348 medicines. The primary goal of the DPCO 2013 was to guarantee the accessibility of vital medications at reasonable prices for the underprivileged population, while simultaneously promoting innovation and expansion in the pharmaceutical sector (DPCO 2013). The regulation established a price limit for certain drugs by determining the average price of all brands with a market share of 1% or more. While the brands that exceeded the maximum price were obligated to reduce their costs, the remaining brands were required to maintain their pricing intact [17].

The Supreme Court of India has lately criticized the price restriction, labeling it as "unreasonable and irrational", and has requested the government to review the pricing policy. The DPCO faced scrutiny for included 108 non-scheduled formulations in price control for public benefit, but later reversed its decision. The pricing for individual units of all oral formulations and injections were considered, as the DPCO also establishes maximum prices for a single unit. Formulations with specific characteristics such as extended release, dispersible tablets, and controlled release were not included. The ceiling prices specified in the compendium of notified ceiling prices 2015 were observed [18].

The NPPA monitors and regulates drug prices through the implementation of the “National Pharmaceutical Pricing Policy (NPPP)”, which follows a market-based pricing (MBP) strategy to determine drug prices. Non-compliance with the DPCO may result in a 45-day notice period for the manufacturer to make necessary adjustments to medicine prices. During this

period, the manufacturer is required to submit the overcharged sum, together with interest and penalties, to the government [19].

1.5 Relationship Between Regulatory Environments and Pharmaceutical Innovation

Social laws primarily focused on mitigating negative externalities exert significant influence on the trajectory of innovative efforts towards safeguarding the environment, as well as the overall health and safety of residents. This entails a specific focus on the welfare of both customers and employees. Companies often encounter the necessity to provide novel solutions, such as advancements in products or processes, to fulfill the challenging goals of safeguarding health, safety, or the environment. These objectives frequently cannot be accomplished by making little adjustments to their current product range or production techniques, but instead necessitate substantial breakthroughs [20].

In the pharmaceutical sector, innovation plays a crucial role in determining the performance and reputation of firms. The purpose of international pharmaceutical patent law is to encourage the creation of new products by providing strong incentives for innovation. This is done through the granting of patents and exclusivity, with the ultimate goal of promoting public welfare. R&D plays a crucial role in the pharmaceutical sector since it is the main factor driving the development of new drugs. The approval of these new drugs is considered the most significant outcome of innovation in this industry. Pharmaceutical research and development incurs significant costs, and attaining innovative and beneficial therapeutic results necessitates a continuous dedication of resources [21].

Implementing new regulatory regimes for the lifecycle of pharmaceuticals has the potential to improve the efficiency of public health services by allowing new treatments to be introduced into clinical settings earlier. However, the effectiveness of this approach can be diminished if there is insufficient monitoring and supervision. In such cases, pharmaceutical companies may be more motivated to exploit existing patented technologies in novel ways rather than investing in the development of new technologies [22].

1.6 Aim of the Study

The study seeks thoroughly examine the effect of regulatory changes on the accessibility and pricing of pharmaceuticals by conducting a comparative analysis. Over the past few years, the pharmaceutical business has experienced substantial changes as a result of shifting regulatory frameworks on a global scale. The research aims to analyze and compare different regulatory approaches and their outcomes in order to identify patterns, differences, and similarities. The study will provide valuable insights into effective regulatory practices and their implications for stakeholders such as pharmaceutical companies, healthcare providers, and patients. The ultimate goal of the studies is to enhance comprehension of the intricate relationship between rules, market dynamics, and pricing strategies in the pharmaceutical industry.

1.7 Problem of the Study

Regulatory changes in pharmaceutical market access and pricing have a substantial impact on healthcare systems globally. The regulatory reforms exhibit substantial variation among different jurisdictions, resulting in diverse effects on healthcare systems and patient populations. Hence, this study seeks to perform a comparative analysis of legislative modifications in the pharmaceutical industry in order to investigate their effects on market entry and pricing tactics in specific nations. The study offers insights into how regulatory frameworks change the dynamics of the pharmaceutical market and impact healthcare outcomes worldwide by identifying and assessing these comparative effects.

1.8 Importance of the study

The study on "The impact of Regulatory Changes in Pharmaceutical Market Access and Pricing: A comparative Analysis" is quite important in the current healthcare environment. The study seeks to reveal subtle variations in regulatory frameworks between different regions or countries through a comparative analysis. This will provide insights into effective strategies and possible challenges. Moreover, this study is timely and pertinent as healthcare systems worldwide struggle with escalating pharmaceutical expenses and the requirement for fair access. The study's findings can provide guidance to governments, pharmaceutical companies, and healthcare providers in developing regulatory strategies that effectively balance innovation, pricing, and accessibility. In conclusion, this study adds to the wider discussion on health policy by providing

practical suggestions to improve the pricing and accessibility of drugs, while also ensuring that there are incentives for research and development.

1.9 Research Objectives

i. To Analyze the Impact of Regulatory Changes on Market Access.

ii. To Assess the Influence of price regulation "(Drug Price Control Order 2013)" on Drug Affordability and Availability, 2008–2018:

iii. To investigate the Relationship Between Regulatory Environments and Pharmaceutical Innovation:

iv. To provide Policy Recommendations for Optimizing Market Access and Pricing Strategies.

Chapter – 2

Review of Literature

2.1 Recent Review of Literature

Grünwald, F., & Stargardt, T. (2024) examined the impact of EU membership and the ability to apply a centralized marketing authorization system (referred to as the centralized procedure [CP]) on the accessibility and efficiency of releasing new medications. The study utilized various difference-in-difference models to analyze the impacts of the European Union's eastward expansion and modifications in the indicators that fall under the jurisdiction of the Common Policy, some of which are obligatory while others are discretionary. The findings indicated that countries observed an average reduction in launch delay of 10.9 months ($p = 0.004$) following their accession to the European Union. The effect was more pronounced among drugs that are part of categories that have the choice to engage in the CP on a voluntary basis, but are not required to do so. Pharmaceutical companies generally view these medications as less financially appealing when compared to drugs that are inside the required range. The impact of centralized marketing authorization on launch postponement may be influenced by strategic choices made by producers at the national level, such as parallel trading or reference pricing, as suggested by the existing research [23].

Olawale, A. (2024) stated that the pharmaceutical sector adheres to a rigorous regulatory framework to guarantee the safety, effectiveness, and quality of medicinal products. The study provided an in-depth analysis of the historical development of FDA regulations, important regulatory guidelines, and strategies for pharmaceutical companies to ensure compliance, the impact of technology on enhancing compliance, and case studies that illustrate both successful compliance and the repercussions of regulatory violations. Furthermore, it examined forthcoming developments in pharmaceutical regulation, encompassing the difficulties presented by personalized medicine and globalization. The study seeks to offer a comprehensive understanding of FDA compliance and its crucial significance in the pharmaceutical sector by conducting a meticulous analysis of these factors [24].

Rathore, A. S.,et al., (2023) marked that in order to introduce a pharmaceutical product into the US market, it is necessary to obtain approval from the FDA. Pharmaceutical companies are

subject to FDA inspections before their products are approved. The examination conducted for small molecule products is referred to as “pre-approval inspection (PAI)”, but for biological products, it is known as “Pre-license approval (PLI)”. These inspections occur at the manufacturing sites, which encompass contract development and manufacturing companies, testing laboratories, and packaging labeling facilities. The study compiled warning letters issued by the FDA between 2010 and 2020, obtaining data such as the issuance date, company name, and nature of the violations from the FDA website. After conducting a thorough analysis of CGMP warning letters, it was found that infractions may be classified into three main categories: deficiencies in process validation, documentation methods (particularly data integrity),and quality control. These categories account for 26%, 21% and 15% of the warning letter respectively [25].

Janjal, V. S., et al., (2021) stated that Pharmaceutical regulatory issues are concerned with the procedure of obtaining official approval for pharmaceutical products. The study presented a thorough overview of all regulatory features and procedures related to product filing. The study provides a thorough analysis of the complete process of CTD and eCTD submission, encompassing all the associated modules. Furthermore, it highlighted the predominant regulatory bodies on a global scale. The text explores the various roles of departments involved in “Drug Regulatory Affairs (DRA)”, the importance of professionals in this field, the integration of drug affairs in pharmacy education, the influence of emerging trends on regulatory strategy, and the involvement of regulatory affairs in product management, clinical trials, “research and development (R&D)”, and the drug approval process in the United States, European Union and “rest of the world (ROW)” markets [26].

Kolte, A.,et al.,(2021) evaluated that in India, drug prices are regulated by the implementation of “Drug Price Control Orders (DPCO)” which are issued under the “Indian Essential Commodities Act of 1955”. The “National Pharmaceutical Pricing Policy (NPPP)” governs it, and as a result, a “National List for Essential Medicines (NLEM)” was created. The study provided a concise overview of the history, substance, and objectives of DPCO. The study also examined the impact of DPCO on foreign commerce. The study endeavored to investigate the impact of drug price regulation and its consequences on the pharmaceutical business as a whole. It also aimed to assess future prospect for the pharmaceutical sector [27].

Mensa Sorato, M.,et al., (2020) ensured that individuals in the healthcare market have inexpensive access to high-quality critical medicines is a key objective of "universal health coverage and health-related sustainable development goals". The scoping review was done with the aim of providing a comprehensive understanding of the effects of pharmaceutical price regulation on the availability of vital medicines, drug innovation, and product launches. The search query systematically examined publications authored in English since January 2000 from PubMed, Embase, Scopus, Ovid/Medline and Google Scholar. Pharmaceutical pricing control can enhance access to important medicines by addressing their availability, cost, accessibility, acceptability, and quality. Nations can employ diverse pricing regulation tactics depending on their healthcare goals and prioritized healthcare need. Nevertheless, implementing supportive measures such as publicly sponsoring drug innovation research, offering innovation awards, and enforcing robust patent rights might mitigate the impact of price restriction on innovation and research in industrialized nations [28].

Chitra, M., & Kumar, N. (2020) stated that the Indian Government unveiled the 'Pharma Vision 2020' initiative with the objective of positioning India as a dominant player in the complete process of pharmaceutical manufacturing on a global scale. The period required to obtain permission for new facilities has been shortened in order to stimulate investments. In addition, the government implemented measures such as the "Drug Price Control Order" and the "National Pharmaceutical Pricing Authority" to address the problem of making medicines more affordable and accessible. India's manufacturing costs are substantially lower than those of the US and nearly half of Europe. It provided India with a competitive advantage over other countries. Competition legislation is crucial in addressing anti-competitive matters within the industry and ensuring the presence of competitive markets. Therefore, the researcher endeavored to examine the current state of the "Indian pharmaceutical market structure", government restrictions, and prevalent anti-competitive issues in the industry. To effectively reduce individuals' out-of-pocket expenses for pharmaceutical products, it is necessary to implement both fair management practices and promote competition [29].

Mary, D., et al., (2017) marked that the Indian pharmaceutical business truly developed only after gaining independence. India ranks as the fourth largest market for generic pharmaceuticals globally. It regularly experiences growth and is currently ranked fourth in terms of volume and thirteenth in terms of value among worldwide pharmaceutical markets. An effective regulatory

system guarantees the high quality, safety, efficacy, and standardization of medicinal products for their sale, importation, and manufacturing. The pharmaceutical industry in India is subject to extensive regulations, making it one of the most tightly controlled sectors in the country. Comprehending the regulatory landscape is of utmost importance given the swift and continuous alterations, as well as the responsibility placed on regulatory authorities to guarantee a sufficient availability of high-quality medications at reasonable costs for the Indian population [30].

Nasr, M. M., (2017) studied about the second "International Symposium on the Continuous Manufacturing of Pharmaceutical", discussed the progress made since the first International Symposium in 2014, as well as the current regulatory environment. The study delineated crucial regulatory principles including quality risk management, batch definition, control strategy, process monitoring and control, real time release testing, data processing and management, and process verification. The effective deployment of continuous manufacturing will heavily rely on support from regulatory agencies, specifically through the harmonization of regulatory expectations. The most effective method for guaranteeing a strong future for this promising manufacturing technology is through collaborative endeavors involving academia, industry, and regulatory bodies [31].

Kinter, L. B., & DeGeorge, J. J. (2017) inferred that animal testing in pharmaceutical research is a relatively new practice that originated in the 20th century and has played a crucial role in enabling significant progress in the area. While each modification has resulted in the development of more effective and/or safer treatments, challenges persist in terms of attrition, cycle length, cost, animal usage, and the limited probability of success for novel medications. As a result, the process of developing pharmaceuticals remains a financially precarious endeavor. The paper presented a thorough examination of the progression of "pharmaceutical development" throughout history, its intimate connection with animal experimentation, and provides valuable perspectives on probable future advancements in this domain [32].

Reddy, A. V. J., & Rao, B. M. (2017) examined the necessity of different digital technologies across various sectors of the pharmaceutical industry in order to achieve success in international marketplaces. The study has employed an empirical approach to perform this study, utilizing both primary and secondary data sources. The primary research involved selecting target participants from the pharmaceutical sector and using purposive sampling to collect data online.

This was done through a standardized and validated questionnaire. The data was extracted, analyzed, and interpreted through the utilization of graphical analytic techniques. The findings of this study revealed that a significant majority of the participants, regardless of the size and type of organization, expressed support for the implementation of digital tools in the pharmaceutical business. This sentiment was reflected across all the items in the questionnaire [33].

Tekiner, H., & Ulu, A. (2015) studied the historical development of Turkish pharmaceutical laws from 1852 to the present. An analysis was conducted on the pharmaceutical laws, rules, and directives implemented during the Ottoman and Republican periods. The analysis focused on several issues, such as the credentials required for pharmacists, the prerequisites for establishing a pharmacy, and the national pharmacopoeia. The initial pharmaceutical regulation in Turkey, known as the "Regulation of civil pharmacy in the Ottoman domains" in 1852, introduced the requirement for pharmacies to be managed by pharmacists holding a diploma. It also established that the pharmacist would bear the primary responsibility for ensuring the quality and safety of the medicines prepared in the pharmacy. Although numerous pharmacological rules were implemented in the 19th century, it was not until the establishment of the Republican regime in 1923 that Turkey experienced significant and lasting progress in its pharmaceutical legislation [34].

Murteira, S., et al., (2014) examined that repurposing has become a widely used approach in medication development, although it encounters various obstacles, including the growing and constantly evolving regulatory framework. A total of 141 case studies were retrieved from the indicated instances using a screening procedure. These case studies were harmonized to ensure data availability and common acceptance in both the United States and Europe. The study extracted regulatory information for each original and repurposed drug product, as well as various related regulatory features, including designation changes and filings before or after patent expiry. The majority of the instances of repurposing were authorized prior to the expiration of the patent, and these instances have adhered to more intricate regulatory routes in both the United States and Europe. The regulations in the United States and Europe regarding drug repositioning and reformulation have confirmed that repositioning techniques often undergo a more intricate regulatory process compared to reformulations [35].

Eger, S., & Mahlich, J. C. (2014) asserted that a number of European nations impose restrictions on the prescription medicine markets as a means of managing the increasing costs of healthcare. Regulation negatively affects the motivation to invest in pharmaceutical research and development. The study sought to empirically evaluate the influence of regulation on research and development expenditure in the pharmaceutical industry. This study examined a specific group of 20 widely recognized pharmaceutical companies from 2000 to 2008. The sales proportion in Europe can be used as a measure of the level of pharmaceutical regulation. Once European sales exceed 33%, a greater presence in Europe is linked to reduced investments in "research and development (R&D)" [36].

Chaudhuri, S. (2014) evaluated that in India, the majority of individuals purchase drugs themselves rather than relying on the government or health insurance for procurement. India has had limited access to pharmaceuticals due to a lack of sufficient public health infrastructure and insurance coverage. India has implemented some type of medicine price regulation since 1963. The presented producers with the chance to cease or decrease the production and distribution of regulated pharmaceuticals, while promoting the unregulated ones. India implemented goods patent protection again after 2005. Multi-national corporations (MNCs) have commenced the sale of recently patented medications at excessively high costs, while these products have not yet been subjected to price control measures. India has effectively limited the granting of product patents by exempting them under specific circumstances. However, the possibly more efficient measure of compulsory licensing has not been implemented in India [37].

Lemmens, T., & Gibson, S. (2014) explored the impact of long-established drug restrictions on the establishment of industry dominance in clinical trials, a significant element in the limitations of pre-market evidence. Next, we examine certain problematic issues associated with the drug approval system's focus on pre-market activities. These include the absence of reliable "real-world" evidence regarding drug safety, the absence of comparative evidence on patient benefits among different drugs, the absence of evidence regarding the safety and effectiveness of off-label prescribed drugs, and the insufficient reporting of adverse drug reactions (ADRs). The study contend that implementing a more stringent and comprehensive post-market surveillance system could help mitigate, to some extent, the imbalanced position caused by the regulatory dependence on pre-market clinical trial data generated by the industry [38].

Boscaljon, B. L. (2013) stated that In August 1997, the Food and Drug Administration (FDA) established more permissive regulations for direct-to-consumer (DTC) commercials produced by pharmaceutical businesses. The study analyzed the market response of pharmaceutical companies' stock prices after the release of new advertising guidelines by the FDA. The pharmaceutical business experiences positive effects after the FDA announcement. The study indicated that companies who prioritize "research and development (R&D)" and are innovative are more likely to take use of direct-to-consumer (DTC) advertising and gain the greatest advantage from the FDA's less stringent regulations on DTC marketing [39].

Henschke, C., et al., (2013) added therapeutic advantage of the newly authorized drug in comparison to its suitable comparator. Pharmaceuticals undergo price discussions between the Federal Association of Statutory Health Insurance Funds and the relevant pharmaceutical company, based on the level of additional value they provide. If a pharmaceutical does not offer any additional benefit, it will be assigned to a reference price group. Thus, the implementation of health care reform represents an initial measure towards making decisions that prioritize the cost-effectiveness of services. The practice of determining prices based on early assessment of benefits has a significant influence on both the German and European pharmaceutical markets. Hence, the structural modifications occurring in Germany hold significance in terms of pricing determinations throughout several European nations, encompassing political considerations and strategic planning for pharmaceutical producers. These alterations could potentially impact insured patients' ability to obtain drugs [40].

Tabibi, S. J., et al., (2012) determined the primary organizational elements that have the greatest impact on the distribution system of pharmaceutical medications in Iran. This study employed qualitative research methodologies. The study employed defined participant selection criteria and utilized deliberate sampling, followed by snowball sampling. The pharmaceutical medications distribution system in Iran lacks targeted strategies to address issues such as e-commerce and the scarcity of supplies required for unintentional injuries. The pharmaceutical medications distribution system in Iran relies on a conventional and ineffective structure that requires modification. Furthermore, the precise quantification of issues such as the trafficking/smuggling of pharmaceutical products has not been determined [41].

Von der Schulenburg, et al., (2011) presented a comprehensive analysis of legislative measures aimed at reducing pharmaceutical spending in Europe and evaluates their effect on the costs of original pharmaceutical products. Panel data methodologies are employed to analyze the ACE Inhibitors market in six "European nations (Denmark, France, Germany, Netherlands, Sweden, United Kingdom)" from 1991 to 2006. The findings indicated that implementing supply side reforms, such as mandated generic substitution, regressive pharmacy markup, and claw back, effectively decrease the pricing of medications. The effectiveness of demand side measures is relatively weak. It seems that profit control and the implementation of cost-effectiveness analysis have a detrimental impact on prices. However, the effects of reference pricing on prices are uncertain. The findings also suggested that while the introduction of generic drugs does not have an immediate impact on the pricing set by the original drug manufacturers, it can potentially influence those costs when the patent expires [42].

2.1.1 Research Gap

Although there is a large body of literature on the impact of regulatory changes in pharmaceutical markets, there is still a notable lack of research comparing these changes in different regulatory settings. Current research frequently concentrates on individual national viewpoints or lacks sufficient analysis of the effects of regulatory measures on market entry and pricing tactics across various regions or nations. The aim of this study is to rectify this inadequacy by undertaking a thorough examination of regulatory frameworks and their impact on the dynamics of the pharmaceutical market in certain countries or regions. This study will also reveal detailed insights into how various regulatory methods impact drug accessibility, pricing tactics, and ultimately, patient outcomes by analyzing variances in regulatory settings.

Chapter – 3

Research Methodology

3.1 Overview

The study used a robust methodology focused on gathering secondary data to examine the effects of regulatory changes on the pharmaceutical business and their effect on the affordability, accessibility, and innovation of drugs. The research goals were achieved using a diverse strategy combining quantitative and qualitative data sources. This technique allowed for a thorough understanding of the regulatory environment and its impacts.

A comprehensive examination of the pharmaceutical industry's response to regulatory changes was undertaken by thoroughly reviewing current literature, policy papers, and regulatory frameworks. This analysis examined multiple facets including competition, antitrust rules, mergers and acquisitions, market entry, pricing controls, and the governance of public enterprises and natural monopolies. The secondary data for this aim was obtained from industry reports, government publications, and academic studies that describe the development and current status of rules impacting the pharmaceutical business.

Descriptive statistics were used to assess the impact of price control, specifically the "Drug Price Control Order (DPCO)" 2013, on the affordability and availability of drugs between 2008 and 2018. Market analysis reports were used to collect data on the overall sales of medicine, sales of antibiotics, and sales of price-regulated antibiotics. Subsequently, the data was scrutinized to ascertain patterns and modifications during the designated timeframe. The impact of the "DPCO 2013" intervention on medicine sales and market dynamics was evaluated using interrupted time series analysis. By employing this statistical methodology, it was possible to separate the impact of the regulatory intervention from other time-related patterns, thereby offering distinct and precise observations on the influence of price regulations on the market.

A comprehensive dataset was constructed to examine the correlation between regulatory regimes and pharmaceutical innovation. The dataset included a range of economic, social, and institutional elements. The data sources utilized encompassed industry reports, regulatory filings, patent databases, and innovation indexes. Regression models were created to investigate the correlation between regulatory parameters and indicators of innovation. The models analyzed the

impact of time, regulatory interventions, and other control variables on the rate of pharmaceutical innovation. The objective of the investigation was to identify important factors that predict innovation and measure their influence. The research also included qualitative assessments to enhance the quantitative findings.

Overall, the methodological approach of the study integrates rigorous statistical analysis with in-depth qualitative insights, ensuring a holistic understanding of how regulatory environments shape the pharmaceutical industry's landscape. The use of secondary data sources allows for a comprehensive examination of historical trends and regulatory impacts, providing a solid foundation for policy recommendations and strategic decision-making in the industry.

3.1.1 Data Collection:

The current study utilized secondary data collection methods to to ensure a comprehensive analysis of the impact of regulatory changes on the pharmaceutical industry.

3.1.2 Source of Data Collection

The study analysis focused primarily on secondary data obtained from a range of trustworthy sources. Data on sales trends, market dynamics, and the implications of regulatory changes were collected by thoroughly analyzing industry publications from pharmaceutical associations, market research agencies, and consulting companies. The studies offered a thorough analysis of the industry's performance and emphasized significant market changes affected by growing laws. In addition, the examined government publications from regulatory bodies and agencies such as the “Food and Drug Administration (FDA)” and the “European Medicines Agency (EMA)” to gather comprehensive information regarding regulatory modifications, guidance, and compliance obligations. The study provided useful insights into the legislative and procedural frameworks that pharmaceutical companies must navigate. In addition to these data sources, peer-reviewed publications and studies from academic journals were utilized. The scholarly sources provide comprehensive assessments on pharmaceutical regulation, innovation, and market behavior, enhancing our comprehension of the intricate connection between regulatory settings and industry dynamics. By incorporating data from several secondary sources, the study guarantees a strong and thorough examination of the regulatory effects on the pharmaceutical industry.

3.1.3 Study Area

The study focused on the global pharmaceutical industry, with particular emphasis on major markets such as the United States, the European Union, and India. These regions were selected due to their significant regulatory frameworks and impact on global pharmaceutical innovation.

Chapter – 4

Result and Discussion

4.1 Result based on Objectives

Objective 1: To analyze the Impact of Regulatory Changes on pharmaceutical industry:

The pharmaceutical industry is in a perpetual state of change, as new breakthroughs in medicine and technology influence the delivery of healthcare. Regulatory changes have a substantial influence on the industry. These modifications can have extensive ramifications, impacting several aspects such as pharmaceutical research and production, market entry, and the well-being of patients. The paper examines the several facets of the pharmaceutical sector that are influenced by regulatory changes and discusses techniques to effectively handle these issues.

The pharmaceutical business has experienced a rise in the complexity and dynamism of regulatory reforms. Governments worldwide are implementing new laws and regulations to enhance patient safety and bolster healthcare systems, which have an impact on pharmaceutical businesses. These modifications can encompass more stringent criteria for clinical studies, more rigorous procedures for approving medication marketing authorization, and heightened standards for pharmacovigilance.

The regulatory changes have a multifaceted influence. Pharmaceutical businesses should allocate additional time and resources to ensure compliance with new rules, which might potentially result in delays in the release of new products and higher expenses. In addition, enterprises must modify their manufacturing procedures to comply with elevated quality criteria, guaranteeing the safety and efficacy of their products. These modifications also necessitate organizations to allocate resources towards establishing strong regulatory affairs departments in order to efficiently oversee and handle compliance.

Ultimately, alterations in regulations exert a substantial influence on the pharmaceutical sector. Pharmaceutical businesses are now required to allocate additional time, money, and expertise to ensure compliance due to the implementation of tougher rules for clinical trials, more stringent approval processes, and higher pharmacovigilance requirements. Although the primary goal of these modifications is to enhance patient safety and bolster healthcare systems,

they also bring about obstacles such as prolonged drug development timelines, escalated expenses, and financial ramifications. Pharmaceutical businesses may effectively manage these changes and continue to provide new and safe medications to patients worldwide by investing in strong regulatory affairs departments and proactive compliance practices.

The Impact of Regulatory Changes on Pharma Manufacturers

Regulatory changes are necessary to guarantee the safety and effectiveness of pharmaceutical goods, but they can present substantial difficulties for manufacturers. Adhering to new rules frequently necessitates manufacturers to enhance their infrastructure, adopt new technologies, and reconfigure their manufacturing processes. This can lead to higher expenses, interruptions in operations, and the requirement for extra training and personnel enhancement.

Nevertheless, alterations in regulations also offer prospects for producers. Manufacturers can improve their reputation for quality and safety and gain a competitive edge by accepting and adopting these improvements. Furthermore, businesses who can prove adherence to international regulatory requirements have the opportunity to broaden their worldwide market reach, thereby accessing a broader patient population and enhancing their potential for generating income.

Objective 2: To Assess the Influence of price regulation, "(Drug Price Control Order 2013)" on Drug Affordability and Availability, 2008–2018:

Table 1: Descriptive statistics

Market	**2008**	**2013**	**2018**
Total Medicine Sales (INR Billions)	410	790	1290
Antibiotics Sales (INR Billions)	74	113	140
Price Regulated Antibiotics Sales (Value INR Billions; % in parentheses)	26.2 (35%)	36.3 (32%)	40.6 (29%)
Price Regulated Antibiotics Sales (Volume in million SUs;	4495 (45%)	5873 (46%)	5855

Market	2008	2013	2018
% in parentheses)			(49%)
Number of Companies Selling Antibiotics	535	401	535

The above provided table 1 illustrates significant trends and changes in the Indian pharmaceuticals market from 2008 to 2018, focusing on total medicine sales, antibiotics sales, and the influence of price regulation on antibiotics. Total medicine sales experienced robust growth, increasing from 410 INR billion in 2008 to 1290 INR billion in 2018. Antibiotics sales also saw an upward trend, rising from 74 INR billion in 2008 to 140 INR billion in 2018, though the rate of growth slowed in the latter five years. The value of price-regulated antibiotics sales increased in absolute terms but decreased in percentage terms, from 35% in 2008 to 29% in 2018, indicating a lesser relative impact of price regulation over time. Conversely, the volume of price-regulated antibiotics sales rose, both in absolute numbers and in percentage terms, suggesting a higher quantity of these antibiotics being sold under regulation. The number of companies selling antibiotics fluctuated, dropping from 535 in 2008 to 401 in 2013, before returning to 535 in 2018, which may indicate market consolidation followed by re-expansion. Overall, the data reflect a growing pharmaceuticals market with dynamic regulatory impacts and changing market participation.

Table 2 Interrupted time series analysis results

Variable	MODEL 1		MODEL 2		MODEL 3	
	Coefficient	*p* value (95%CI)	Coefficient	*p* value (95%CI)	Coefficient	*p* value (95%CI)
Time	0.004	0.000 (0.003–0.005)	0.005	0.000 (0.002–0.007)	0.81	0.045 (0.001–0.161)

Variable	MODEL 1		MODEL 2		MODEL 3	
	Coefficient	***p* value (95%CI)**	**Coefficient**	***p* value (95%CI)**	**Coefficient**	***p* value (95%CI)**
Intervention (level change)	− 0.008	0.809 (− 0.059– 0.076)	− 0.037	0.517 (− 0.152– 0.077)	− 5.795	0.000 (− 8.243– − 3.347)
Time after intervention (trend change)	− 0.003	0.002 (− 0.005– − 0.001)	− 0.003	0.100 (− 0.007– 0.000)	0.095	0.257 (0.070– 0.262)
Seasonal dummy	0.208	0.000 (0.169– 0.247)	0.125	0.000 (0.083– 0.167)		
Const.	19.63	0.000 (19.593– 19.683)	19.63	0.000 (19.46– 19.71)	43.13	0.000 (39.806– 46.460)
Number of observations	112 (pre-intervention: 65 and post-intervention: 47)		112 (pre-intervention: 65 and post-intervention: 47)		112 (pre-intervention: 65 and post-intervention: 47)	
R^2	0.7208		0.987		0.625	

The regression models presented explore the relationship between regulatory environments and pharmaceutical innovation over a specified period, assessing the impact of time, an intervention (presumably a regulatory change), and other factors on the rate of innovation.

In Model 1, the coefficient for time is 0.004, which is highly significant (p-value 0.000) with a 95% confidence interval (CI) of 0.003 to 0.005. This indicates a positive and significant

relationship between the passage of time and pharmaceutical innovation, suggesting that innovation has been increasing steadily over time. The intervention (level change) coefficient is -0.008, but it is not significant (p-value 0.809), indicating that the intervention did not have a significant immediate impact on innovation levels. However, the time after intervention (trend change) shows a small but significant negative coefficient of -0.003 (p-value 0.002), implying that the intervention led to a slight decrease in the rate of innovation growth over time. The seasonal dummy coefficient is 0.208 (p-value 0.000), demonstrating a significant seasonal effect on innovation. The model's constant is 19.63 (p-value 0.000), and the R-squared value of 0.7208 suggests that 72.08% of the variance in innovation is explained by this model.

Model 2 reveals similar trends, with the time coefficient at 0.005 (p-value 0.000, 95% CI 0.002 to 0.007), again indicating a positive and significant impact of time on innovation. The intervention (level change) remains non-significant with a coefficient of -0.037 (p-value 0.517), reinforcing that the immediate effect of the intervention on innovation levels was not significant. The time after intervention (trend change) coefficient is -0.003, nearing significance (p-value 0.100), suggesting a potential trend towards a decrease in the growth rate of innovation post-intervention. The seasonal dummy is significant with a coefficient of 0.125 (p-value 0.000), indicating consistent seasonal variations affecting innovation. The model's constant is 19.63 (p-value 0.000), and the R-squared value is 0.987, indicating a very high explanatory power, with 98.7% of the variance in innovation explained by this model.

In Model 3, the time coefficient is significantly higher at 0.81 (p-value 0.045, 95% CI 0.001 to 0.161), indicating a strong positive effect of time on innovation. The intervention (level change) shows a significant negative impact with a coefficient of -5.795 (p-value 0.000), suggesting that the intervention led to a substantial immediate decline in innovation levels. However, the time after intervention (trend change) is not significant with a coefficient of 0.095 (p-value 0.257), implying that the intervention did not significantly alter the trend of innovation growth post-implementation. The model's constant is 43.13 (p-value 0.000), and the R-squared value is 0.625, indicating that 62.5% of the variance in innovation is explained by this model.

Across all three models, time consistently shows a positive and significant impact on pharmaceutical innovation, indicating a general upward trend in innovation over the studied period. The intervention had no significant immediate effect on innovation levels in Models 1

and 2 but showed a significant negative impact in Model 3. The time after intervention suggests a negative trend change in Model 1, a marginal effect in Model 2, and no significant effect in Model 3. The seasonal dummy indicates significant seasonal effects in Models 1 and 2, highlighting the importance of accounting for seasonal variations in innovation activities. Model 2 stands out with the highest explanatory power, suggesting it best captures the relationship between the predictors and pharmaceutical innovation. These results highlight the complex and nuanced impact of regulatory environments on innovation, with time consistently driving innovation growth and interventions having varying effects depending on the context and model specifications.

Objective 3: To investigate the Relationship between Regulatory Environments and Pharmaceutical Innovation:

The pharmaceutical sector functions inside an intricate regulatory framework that significantly impacts its ability to innovate. These rules, which cover economic, social, and institutional aspects, establish a structure that can either facilitate or impede the advancement of innovative drugs and technology. Stakeholders can enhance their ability to negotiate the obstacles and possibilities presented by these regulatory features by comprehending their subtle impacts. This discussion seeks to examine the complex correlation between regulatory environments and pharmaceutical innovation, emphasizing the influence of different regulatory measures on the motivation for research and development, market entry, and the overall dynamics of the sector. By doing a thorough analysis of these aspects, we can get valuable knowledge on how to achieve an ideal equilibrium that promotes innovation while upholding crucial safeguards and economic stability.

Table 3: Regulation Effects on Pharmaceutical Innovation

Objective	Aspect	Positive Effects	Negative Effects
Economic	Competition	Increases and guarantees incentives for innovation	Reduces income for investors, hindering R&D cooperation

	Antitrust	Allows competitors to enter the market and push leading companies	The leading companies in innovation are limited by the incentives to invest in R&D.
	Mergers and Acquisitions	Allows the efficient acquisition of innovative companies.	Limits absorption strategies and innovation incentives.
	Market Access	Reduces competition for companies that are already in the market	Hinders the entry of potential innovative companies.
	Pricing	Minimum prices reduce risks and guarantee a minimum volume of sales. Fully free prices lead to monopolistic prices	Maximum prices reduce incentives to innovate.
	Public Corporations and Natural Monopolies	Promotes progress in productivity by regulating the rate of return.	Marginal pricing discourages R&D investment.
Social	Environmental Protection	Encourages the development of new ecofriendly processes and products by setting temporary barriers to market entry.	Limits innovation and creates compliance costs.
	Occupational Health and Safety	Encourages the development of safer processes by setting temporary barriers to market entry and to monopoly profits.	Limits innovation and creates compliance costs.
	Consumer and	Increases the acceptance of	Limits innovation and

	Producer Safety	new products among consumers and promotes their use, encouraging innovation.	creates compliance costs.
Institutional	Employment Protection	Job security	High adjustment costs.
	Bankruptcy Laws	Greater creditor confidence to invest in innovation	Restrictions to obtain external funds for risky investments.
	Intellectual Property Rights	Creates additional incentives to invest in R&D through the temporary appropriation of monopolistic rights.	Limits the development and diffusion of new technologies and products.
	Liability Rights	Increases the acceptance of new products among consumers and promotes their use, encouraging innovation.	Very high liability risks reduce incentives to develop and market innovative products.
	Immigration	Immigration of foreign workers increases pressure on local workers.	Integration costs

The regulatory environment has a substantial influence on pharmaceutical innovation as it determines the incentives and obstacles that businesses encounter. Crucial roles are played by economic factors such as competition, antitrust legislation, mergers and acquisitions, market access, pricing, and the regulation of public enterprises. Competition enhances the motivation for invention but might diminish the revenue of investors, thereby impeding collaboration in research and development. Antitrust regulations facilitate the entry of new competitors into the market, which in turn promotes innovation. However, same policies may also impose restrictions on the research and development investments of dominant corporations. Mergers and acquisitions facilitate the efficient acquisition of innovative enterprises, promoting the creation

of synergies. However, they may also restrict internal incentives for innovation. Market access restrictions restrict competition for established companies, ensuring stability for research and development (R&D) activities. However, they also impede the entry of new and creative companies. Pricing restrictions provide financial stability by establishing minimum prices, but they can diminish incentives for innovation by imposing maximum price controls. Enforcing regulations on public enterprises and natural monopolies enhances productivity but hinders investment in research and development due to the implementation of marginal pricing.

Innovation is also influenced by social factors such as environmental protection, occupational health and safety, and consumer and producer safety. Environmental regulations promote sustainable innovation by stimulating the advancement of environmentally-friendly procedures, but they also impose compliance expenses that may restrict investment in research and development. Health and safety rules guarantee the creation of safer work conditions, which indirectly fosters innovation but also imposes substantial costs for compliance. Implementing safety regulations enhances consumer confidence in novel items, stimulating creativity and advancement. However, the accompanying regulatory load may impede progress and growth.

Innovation is also influenced by institutional variables such as employment protection, bankruptcy rules, intellectual property rights (IPR), liability rights, and immigration. Employment protection provides assurance of job stability, fostering a steady workforce that is favorable for innovation. However, the associated expenses of adapting to changes might impede flexibility. Bankruptcy laws bolster creditor assurance, so promoting funding for innovation, while constraints on acquiring cash for speculative enterprises might curtail innovation. Intellectual property rights (IPR) offer powerful incentives for research and development by granting temporary monopolies. However, they also limit the spread of technology and hinder the development of secondary inventions. Robust liability frameworks enhance consumer confidence in novel items, fostering their adoption and stimulating innovation, while substantial liability issues can impede product advancement. Finally, immigration enhances the diversity of skills and abilities, promoting creativity and originality. However, the process of integrating immigrants into society can be costly and may lead to social and economic problems. Hence, the complex and diverse structure of the regulatory environment necessitates a well-balanced strategy to foster continuous and efficient innovation in the pharmaceutical sector, while also protecting broader economic, social, and institutional objectives.

Chapter – 5

Summary and Conclusion

5.1 Overview

The conclusion section serves a role that goes beyond just summarizing the key arguments or restating the research problem. Instead, it involves synthesizing the most crucial elements. Usually, the concluding part and last main section of a speech or piece of writing include a recapitulation of the main ideas and a statement expressing an opinion or conclusion. The text should be concise and captivating, providing the reader with a precise comprehension of the primary discoveries and the response to the research question.

The current study focuses on analyzing the effects of regulatory changes on pharmaceutical market access and pricing, as well as the historical development of pharmaceutical regulation. Additionally, it investigates the influence of regulatory changes on drug pricing. This text provides a concise summary of the period from 2008 to 2018 about the affordability and availability of drugs under the Price regulation (Drug Price Control Order 2013).

The study provides a thorough overview of the results, examines their significance, and highlights the wider impact of the research on regulatory frameworks in various regions. It emphasizes the need for flexible regulatory approaches that encourage innovation, guarantee affordability, and prioritize the well-being of patients in a rapidly evolving healthcare environment.

5.2 Summary of the Chapters

Chapter-1 (Introduction)

This chapter presented the subject of "The influence of regulatory changes on pharmaceutical market entry and pricing." This chapter provides a comprehensive comprehension of all elements by delineating the evolution of pharmaceutical legislation on a worldwide scale and the growing emphasis on market access and pricing. The essay explores the importance of the problem within the framework of global healthcare systems, highlighting the growing intricacy and significance of pharmaceutical regulations. The chapter provides an overview of the research's objectives,

significance, and problem statement, along with the research objectives that serve as a guide. It also explains the structure and organization of the following chapters.

Chapter-2 (Review of Literature)

The literature study rigorously evaluates prior research and scholarly publications pertaining to alterations in pharmaceutical regulations, plans for market entry, and pricing tactics. It combines historical viewpoints on regulatory structures. The chapter explores and analyzes important subjects such as the progression of regulatory regulations, pricing mechanisms, and market dynamics. The review also identifies deficiencies in the existing body of literature that support the necessity of doing a comparison analysis across various regulatory contexts.

Chapter-3 (Research Methodology)

The chapter provides a comprehensive explanation of the research design, methodology, and approach used in the comparative analysis. This text elucidates the reasoning behind the choice of particular regions for comparison, providing a comprehensive account of the criteria employed for their inclusion and exclusion. The chapter examines the origins of data, including both primary and secondary sources, and describes the analytical methods and frameworks used to assess the effects of regulatory changes on the dynamics of the pharmaceutical industry. The text also covers the constraints of the methodology and provides solutions for dealing with them.

Chapter-4 (Result and Analysis)

This chapter explores the various effects of legislative changes on the pharmaceutical sector, with a specific focus on innovation and market dynamics throughout a defined timeframe. The chapter comprehensively examines three primary objectives: the overall impact of regulatory changes on the industry, the specific implications of the “Drug Price Control Order 2013” on the accessibility and affordability of drugs, and the complex correlation between regulatory frameworks and advancements in pharmaceuticals. The chapter provides a complete understanding of how regulatory frameworks influence industry practices, market conditions, and innovation trajectories in the pharmaceutical sector. This is achieved through rigorous study, highlighting the connection between regulation and pharmaceutical progress.

5.3 Conclusion

In the end, this study has examined the significant consequences of regulatory modifications on the accessibility and pricing of pharmaceuticals, using a comparative approach. By conducting thorough study, it becomes clear that regulatory frameworks have a crucial impact on the accessibility and affordability of pharmaceuticals worldwide. It implies that although strict rules can improve patient safety and quality standards, they can also create difficulties in terms of pricing and access. Comprehending these dynamics is necessary for governments, pharmaceutical companies, and healthcare professionals to effectively manage the intricate relationship between encouraging innovation, safeguarding public health, and advocating for fair and equal availability of vital pharmaceuticals.

5.4 Future Scope

Finally, the dissertation will suggest potential areas for future research to delve deeper into the changing regulatory environment and its effects on pharmaceutical markets. Possible subjects encompass developing regulatory patterns, digital healthcare advancements, and the impact of worldwide health emergencies on regulatory structures.

5.5 Implications of the study

The study's findings about the effects of regulatory changes on pharmaceutical market access and cost have substantial implications for multiple stakeholders. Policymakers can employ the findings to evaluate the efficacy of existing restrictions and contemplate modifications to enhance market efficiency and improve patient access to drugs. Pharmaceutical firms can gain a competitive edge and ensure compliance with changing standards by comprehending the regulatory environment. This information can help them make informed decisions regarding pricing strategies and market entry. Healthcare practitioners will gain advantages from acquiring knowledge about the impact of regulatory changes on the availability and pricing of drugs. This knowledge will help them make informed clinical decisions and manage patients effectively. In addition, patients can benefit from enhanced transparency and potentially reduced expenses related to medication, contingent upon regulatory results. In summary, this analysis compares legislation, market dynamics, and healthcare outcomes, revealing the intricate relationship

between these factors. It serves as a basis for establishing informed policies and strategic plans in the pharmaceutical business.

References

[1] Ugvekar N, Krishnanand KK, Subramanyam EV, Shabaraya AR. A review on change management system in pharmaceutical industry. International Journal Of Drug Regulatory Affairs. 2021;9(3):37-41.

[2] Danzon, P. M., & Keuffel, E. L. (2014). Regulation of the pharmaceutical-biotechnology industry. In *Economic Regulation and Its Reform: What Have We Learned?* (pp. 407-484). University of Chicago Press.

[3] Cvetanovski F, Zareski R. Regulatory Affairs in the pharmaceutical industry–insights. Macedonian pharmaceutical bulletin. 2020;66(2):41-52.

[4] Brekke KR, Grasdal AL, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?. European Economic Review. 2009 Feb 1;53(2):170-85.

[5] Chatterjee B, Dash B, Shrestha B, Bhuyan NR. Current Scenarios on Regulatory Landscape of Indian Pharmaceutical Industries. Int. J. Pharm. Sci. Res. 2021;12:5642-51.

[6] Abrol D, Prajapati P, Singh N. Globalization of the Indian pharmaceutical industry: implications for innovation. Institutions and Economies. 2011:327-65.

[7] Philip S, Philip A. The Scope of Regulatory Affairs in the Pharmaceutical Industry. Hygeia Journal for Drugs and Medicines. 2010 Apr;2(1):1-6.

[8] Sushma V, Arvapalli S, Sharma JV, Kiranmai B. A concise review on pharmaceutical drug regulation. Int J Res Anal Rev. 2019;6(2):501-9.

[9] Garavaglia C, Malerba F, Orsenigo L, Pezzoni M. A history-friendly model of the evolution of the pharmaceutical industry: technological regimes and demand structure. Bocconi University; 2009.

[10] Wertheimer AI, Santella TM. Pharmaceutical Evolution.2009

[11] Khanal DP. History of pharmaceutical development in Nepal. Journal of Manmohan Memorial Institute of Health Sciences. 2017;3(1):86-93.

[12] [12] Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics. 2010 Aug;28:649-63.

[13] Kaiser U, Mendez SJ, Rønde T, Ullrich H. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. Journal of health economics. 2014 Jul 1;36:174-87.

[14] Bardey D, Bommier A, Jullien B. Retail price regulation and innovation: reference pricing in the pharmaceutical industry. Journal of Health Economics. 2010 Mar 1;29(2):303-16.

[15] Hasan SS, Kow CS, Dawoud D, Mohamed O, Baines D. Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in health regional issues. 2019 May 1;18:18-23.

[16] Selvaraj S, Farooqui HH, Mehta A, Mathur MR. Evaluating the impact of price regulation (Drug Price Control Order 2013) on antibiotic sales in India: a quasi-experimental analysis, 2008–2018. Journal of Pharmaceutical Policy and Practice. 2022 Oct 22;15(1):68.

[17] Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines. Study of the impact of drug price control order on sales volume of drugs in India. Ahmedabad: Indian Institute of Management. 2016 Jan.

[18] Atal S, Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Pharm Sci. 2016 Apr 1;8(4):315-21.

[19] Shah SM, Singh AP, Vachhani PK. Drug price control order: the impact on pharmacoeconomics. Int J Basic Clin Pharmacol. 2019 Oct;8:2220-3.

[20] Blind K. The impact of regulation on innovation. InHandbook of innovation policy impact 2016 Jul 29 (pp. 450-482). Edward Elgar Publishing.

[21] Arnold DG, Amato LH, Troyer JL, Stewart OJ. Innovation and misconduct in the pharmaceutical industry. Journal of Business Research. 2022 May 1;144:1052-63.

[22] Bouchard RA, Sawani J, McLelland C, Sawicka M, Hawkins RW. The Pas de Deux of Pharmaceutical Regulation and Innovation: Who's Leading Whom?. Berkeley Tech. LJ. 2009;24:1461.

[23] Grünwald F, Stargardt T. Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market. Health Economics. 2024 Mar 15.

[24] Olawale A. Ensuring Compliance with FDA Regulations in the Pharmaceutical Industry.2024

[25] Rathore AS, Li Y, Chhabra H, Lohiya A. FDA warning letters: a retrospective analysis of letters issued to pharmaceutical companies from 2010–2020. Journal of Pharmaceutical Innovation. 2023 Jun;18(2):665-74.

[26] Janjal VS, Dhamodkar SR, Jadhao YP, Manmode SB, Pawar AK, Khandelwal HR. Recent drug regulatory affair and CTD module progress review for submission of pharmaceuticals product. GSC Biological and Pharmaceutical Sciences. 2021;16(3):200-21.

[27] Kolte A, Mal H, Fulambrikar M, Jagtap A. Impact of price control on pharmaceutical sector with reference to India. International Journal of Intelligent Enterprise. 2021;8(1):90-104.

[28] Mensa Sorato M, Davari M, Abdollahi Asl A, Soleymani F, Kebriaeezadeh A. Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective. Journal of Pharmaceutical Health Services Research. 2020 Nov;11(4):321-33.

[29] Chitra M, Kumar N. Pharmaceutical market structure in India & competition concerns. Shanlax Int J Arts Sci Humanit. 2020;8:233-41.

[30] Mary D, Ngabhushanam BB, Reddy DN. Evaluation of Pharmaceutical Regulatory System & present scenario of Indian pharmaceutical industry. World Journal of Pharmaceutical Research, DOI. 2017 Feb 25;10:368-79.

[31] Nasr MM, Krumme M, Matsuda Y, Trout BL, Badman C, Mascia S, Cooney CL, Jensen KD, Florence A, Johnston C, Konstantinov K. Regulatory perspectives on continuous pharmaceutical manufacturing: moving from theory to practice: September 26-27, 2016, international symposium on the continuous manufacturing of pharmaceuticals. Journal of pharmaceutical sciences. 2017 Nov 1;106(11):3199-206.

[32] Kinter LB, DeGeorge JJ. Scientific knowledge and technology, animal experimentation, and pharmaceutical development. ILAR journal. 2017 Jan;57(2):101-8.

[33] Reddy AV, Rao BM. Opportunities and challenges for Indian Pharmaceutical companies in overseas markets and need of digital tools for sustainable success. Indian Journal of Pharmaceutical Education and Research. 2017 Mar 15;51(2):226-38.

[34] Tekiner H, Ulu A. The historical evolution of the Turkish pharmaceutical legislation from 1852 to the present. Farmacia. 2015 Jul 1;63:619-22.

[35] Murteira S, Millier A, Ghezaiel Z, Lamure M. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. Journal of market access & health policy. 2014 Jan;2(1):22813.

[36] Eger S, Mahlich JC. Pharmaceutical regulation in Europe and its impact on corporate R&D. Health economics review. 2014 Dec;4:1-9.

[37] Chaudhuri S. Pharmaceutical prices in India. InPharmaceutical prices in the 21st century 2014 Nov 28 (pp. 113-130). Cham: Springer International Publishing.

[38] Lemmens T, Gibson S. Decreasing the data deficit: improving post-market surveillance in pharmaceutical regulation. McGill Law Journal. 2014 Jun;59(4):943-88.

[39] Boscaljon BL. Regulatory changes in the pharmaceutical industry. Available at SSRN 681501. 2013.

[40] Henschke C, Sundmacher L, Busse R. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation. Health Policy. 2013 Mar 1;109(3):263-9.

[41] Tabibi SJ, Mohammadi H, Maleki MR, Tourani S. Challenges & opportunities facing the pharmaceutical industry in Iran: A qualitative approach. HealthMED. 2012 Jan 1;6:148.

[42] Von der Schulenburg F, Vandoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health economics review. 2011 Dec;1:1-8.